SEC Tracker
Get the app

Glycomimetics CBIO

Glycomimetics says Timothy Pearson resigned from the board

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 10.5
Material contract
Exhibit 10.7
Material contract
Exhibit 10.8
Material contract
Exhibit 10.20
Material contract
Exhibit 99.1
Press release
  • Signs a material agreement (1.01)
  • Completes an acquisition or sale of assets (2.01)
  • Reports quarterly results (2.02)
  • Changes shareholder rights (3.03)
  • Changes its auditor (4.01)
  • Reports a change in control (5.01)
  • Reports an executive or board change (5.02)
  • Amends its charter or bylaws (5.03)
  • Changes its ethics code (5.05)
  • Changes its shell company status (5.06)
  • Makes a Regulation FD disclosure (7.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Glycomimetics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Omeros OMER public float $172M, Jun 30, 2025
  2. Lexicon Pharmaceuticals LXRX public float $170M, Jun 30, 2025
  3. XOMA Royalty XOMA public float $168M, Jun 30, 2025
  4. 4D Molecular Therapeutics FDMT public float $166M, Jun 30, 2025
  5. Editas Medicine EDIT public float $191M, Jun 30, 2025